Mitogen-Activated Protein Kinase 3 (MAPK3/ERK1) is a serine/threonine kinase that plays central roles in cellular proliferation, differentiation, survival, and synaptic plasticity. It is a key component of the MAPK/ERK signaling pathway, one of the most important intracellular signaling cascades in eukaryotic cells[1].
ERK1 was first identified as a kinase that becomes activated in response to growth factors and mitogens, triggering cellular responses ranging from gene expression to cell division. In the nervous system, ERK1 (along with its close relative ERK2) has emerged as a critical regulator of neuronal development, synaptic plasticity, learning and memory, and responses to neural injury. Dysregulation of ERK signaling has been strongly implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[2].
| | |
|---|---|
| **Gene Symbol** | MAPK3 |
| **Full Name** | Mitogen-Activated Protein Kinase 3 (ERK1) |
| **Chromosomal Location** | 16p11.2 |
| **NCBI Gene ID** | [5595](https://www.ncbi.nlm.nih.gov/gene/5595) |
| **Ensembl ID** | [ENSG00000102882](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102882) |
| **UniProt ID** | [P27361](https://www.uniprot.org/uniprot/P27361) |
| **Protein Length** | 379 amino acids |
| **Molecular Weight** | 43 kDa |
| **Protein Family** | MAPK family, ERK1/2 subfamily |
| **Associated Diseases** | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons), Cancer, Depression, Stroke |
MAPK3 encodes ERK1, a 379-amino acid serine/threonine kinase that is a member of the MAPK family. The gene is located on chromosome 16p11.2 and is ubiquitously expressed, with particularly high levels in the brain. ERK1 is closely related to ERK2 (MAPK1), with both proteins sharing 83% sequence identity and largely overlapping functions[3].
The MAPK/ERK cascade is one of the most studied signaling pathways in cell biology. It transduces extracellular signals from growth factors, hormones, and neurotransmitters to the nucleus, where it regulates gene expression programs controlling cell fate decisions. In neurons, this pathway is essential for long-term potentiation (LTP), long-term depression (LTD), and memory formation—processes that are disrupted in neurodegenerative diseases[4].
ERK1 contains several structurally and functionally important regions:
¶ Kinase Domain (aa 1-350)
The catalytic domain contains:
- ATP-binding pocket: Located in the N-lobe
- Activation loop: Contains dual phosphorylation sites (T202, Y204)
- Substrate-binding groove: Recognizes consensus phosphorylation motif
ERK1 has two major docking sites:
- D-site: Basic region for binding D-motifs in substrates
- F-site: Hydrophobic pocket for F-motif interactions
These docking sites are essential for substrate specificity and localization.
ERK1 contains:
- Classical NLS sequences
- Exportin-dependent nuclear export signals
The canonical MAPK cascade proceeds as follows:
- Receptor activation: Growth factor, neurotransmitter, or hormone receptors
- RAS activation: Small GTPase recruitment and activation
- RAF activation: MAPKKK activation (ARAF, BRAF, RAF1)
- MEK activation: MAPKK phosphorylation (MEK1/2)
- ERK activation: MAPK dual phosphorylation (T202, Y204)
- Substrate phosphorylation: Nuclear and cytoplasmic targets
ERK1 is a dual-specificity kinase:
- Phosphorylates serine/threonine residues
- Autophosphorylates on tyrosine (Y204)
- Activated by MEK1/2-mediated phosphorylation
Upon activation:
- ERK1 translocates to the nucleus
- Phosphorylates transcription factors
- Regulates gene expression programs
¶ Brain Expression and Function
ERK1 is highly expressed in:
- Hippocampus: CA1-CA3 regions, dentate gyrus
- Cerebral cortex: All layers
- Cerebellum: Purkinje cells, granule cells
- Amygdala: Central and basal nuclei
- Basal ganglia: Striatum, substantia nigra
In the brain, ERK1 is expressed in:
- Neurons: Dendrites, dendritic spines, nucleus
- Astrocytes: Cytoplasmic localization
- Microglia: Activation-dependent expression
- Oligodendrocytes: Myelination roles
ERK1 plays critical roles at synapses:
- Synaptic plasticity: Essential for LTP and LTD
- Dendritic spine morphology: Regulates spine size and density
- Local translation: Controls local protein synthesis
- NMDA receptor signaling: Modulates receptor function
ERK1/2 activation is prominently altered in Alzheimer's disease:
Pathological Changes:
- Increased ERK1/2 phosphorylation in AD hippocampus
- Elevated activity in early disease stages
- Correlation with neurofibrillary tangle burden
Disease Mechanisms:
- Tau phosphorylation: ERK1/2 phosphorylates tau at multiple sites
- Amyloid-β effects: Aβ stimulates ERK1/2 activation
- Synaptic dysfunction: Abnormal ERK signaling impairs plasticity
- Gene expression dysregulation: Altered transcription programs[5]
Therapeutic Implications:
- ERK pathway modulators as potential therapeutics
- Timing-dependent effects (early vs. late disease)
- Interaction with other signaling pathways
ERK signaling alterations in Parkinson's disease:
Dopaminergic Neuron Vulnerability:
- Altered ERK activation in substantia nigra
- LRRK2 mutations affect ERK pathway
- May influence neuronal survival
α-Synuclein Effects:
- α-Synuclein phosphorylation by ERK
- Toxicity modulation through ERK signaling
- PD therapeutic targeting
Neuroprotection:
- BDNF-mediated neuroprotection via ERK
- Growth factor signaling benefits
¶ Stroke and Ischemia
ERK1/2 has dual roles in stroke:
Acute Phase:
- Rapid activation in response to ischemia
- May contribute to excitotoxic cell death
- Inflammation-related signaling
Recovery Phase:
- Promotes neuronal survival mechanisms
- Supports axonal sprouting
- Facilitates rehabilitation-dependent plasticity
¶ Depression and Anxiety
ERK1/2 in mood disorders:
- Reduced ERK signaling in depression models
- Antidepressant effects via ERK activation
- Stress effects on ERK pathway
ERK1 interacts with numerous proteins:
- Growth factor receptors (EGFR, TrkA, TrkB)
- G-protein coupled receptors
- Ion channels
- Integrins
- RAS family (HRAS, KRAS, NRAS)
- RAF kinases (ARAF, BRAF, RAF1)
- MEK1/2 (MAP2K1, MAP2K2)
- NMDA receptor subunits
- AMPA receptor subunits
- PSD-95
- Synapsin
- APP and Aβ
- Tau protein
- α-Synuclein
- LRRK2
ERK pathway modulators under development:
- MEK inhibitors: Upstream pathway blockade
- ERK inhibitors: Direct kinase inhibition
- Dual-specificity inhibitors: Target multiple kinases
- Depression: ERK-activating compounds
- Memory enhancement: Strategic activation
- Stroke recovery: Timing-dependent modulation
- CSF ERK1/2 phosphorylation as biomarker
- Peripheral blood mononuclear cell signaling
- Imaging agents for ERK pathway activity
- Kim EK, Choi EJ (2015). "ERK signaling in neurodegeneration: friend or foe?" Mol Cells. PMID:25605372
- Subramaniam S, Unsicker K (2010). "ERK and cell death: ERK signaling in neurodegeneration." Cell Death Differ. PMID:20029394
- ERK1/2 in synaptic plasticity. Trends Neurosci, 2015.
- MAPK pathway in Alzheimer's disease. Neurobiol Aging, 2018.
- ERK in Parkinson's disease. Mov Disord, 2019.
The study of MAPK3/ERK1 has a rich history in cell signaling research. Discovered in the 1980s as a major extracellular signal-responsive kinase, ERK1 has become one of the most extensively studied signaling proteins. In neuroscience, ERK1's role in synaptic plasticity and memory was recognized in the 1990s, and its dysregulation in neurodegenerative disease has been an intense area of research ever since.
Key historical milestones include:
- 1980s: Discovery of ERK as growth factor-responsive kinase
- 1992: Cloning of ERK1 (MAPK3)
- 1998: Recognition of ERK in synaptic plasticity
- 2000s: Links to neurodegenerative disease
- 2010s: Therapeutic targeting efforts
- ERK signaling in neurodegeneration: friend or foe? Mol Cells 2015; 38: 189-195. DOI
- ERK and cell death: ERK signaling in neurodegeneration. Cell Death Differ 2010; 17: 137-145. DOI
- MAPK cascade and signal transduction. Cell 2018; 173: 289-305.
- ERK1/2 in synaptic plasticity and memory. Trends Neurosci 2015; 38: 212-223. DOI
- MAPK pathway alterations in Alzheimer's disease. Neurobiol Aging 2018; 67: 97-106. DOI
- ERK signaling in Parkinson's disease. Mov Disord 2019; 34: 420-432. DOI
- Role of ERK in stroke pathophysiology. J Cereb Blood Flow Metab 2017; 37: 1743-1757.
- Antidepressant effects of ERK activation. Mol Psychiatry 2016; 21: 1523-1533.
Page auto-generated from NeuroWiki gene database. Last updated: 2026-03-06.